Drugs / Lorpucitinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04552197 | Sep → Dec 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lorpucitinib | “Lorpucitinib (JNJ-64251330) is an oral, small molecule, pan-JAK inhibitor.” PMID 38159266 ↗ Jan 2024 |
| Known as | JNJ-64251330 | “Lorpucitinib (JNJ-64251330) is an oral, small molecule, pan-JAK inhibitor.” PMID 38159266 ↗ Jan 2024 |
| Action | Inhibit | “Lorpucitinib (JNJ-64251330) is an oral, small molecule, pan-JAK inhibitor.” PMID 38159266 ↗ Jan 2024 |
| Modality | Small molecule | “Lorpucitinib (JNJ-64251330) is an oral, small molecule, pan-JAK inhibitor.” PMID 38159266 ↗ Jan 2024 |
| Route | Oral | “Lorpucitinib (JNJ-64251330) is an oral, small molecule, pan-JAK inhibitor.” PMID 38159266 ↗ Jan 2024 |